Floatz logo

Cyclophosphamide

B2 Thymoma

Beijing BiotechSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the B2 Thymoma cohort.

Asset / SponsorPhaseRating
Regorafenib
Istituto Clinico Humanitas
Phase 2B
Eb-Car5-Nk
Beijing Biotech
Phase 1/2CC
Eb-Car30-Nk
Beijing Biotech
Phase 1/2CC
Fludarabine
Beijing Biotech
Phase 1/2CC
Eb-Carmsln-Nk
Beijing Biotech
Phase 1/2CC
Rimiducid
Beijing Biotech
Phase 1/2CC

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →